Juncell Therapeutics Announces Data on Feeder-free IL-2-Independent TIL Manufacturing Process at ASGCT Annual Meeting 2025
SHANGHAI, April 29, 2025 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech specializing in developing innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies for cancer, today...